Liquid biopsy and precision medicine in lymphoma
The Alig Lab advances liquid biopsy and precision medicine to improve the understanding, monitoring, and treatment of lymphoma. Based at the Department of Hematology and Stem Cell Transplantation, University Hospital Essen, we develop ultrasensitive circulating tumor DNA (ctDNA) technologies to enhance diagnosis and response assessment. By combining genomic profiling, computational analysis, and pre-clinical functional models, we investigate molecular heterogeneity, track clonal evolution, and detect minimal residual disease, aiming to uncover resistance mechanisms and guide individualized patient care.
Our lab is funded by the Max-Eder Junior Research Group Program of the German Cancer Aid (Deutsche Krebshilfe).
